The Taizhou Medical High Tech Zone – located in Taizhou city, in East China's Jiangsu province – is experiencing significant growth and development in its healthcare industry.
From January to August, the park focused on attracting large projects, resulting in 42 new projects signed up costing a combined 10.74 billion yuan ($1.47 billion).
These include the expansion of HPV vaccine production, as well as the construction of medical equipment production and R&D bases.
The zone has also obtained numerous drug registration approvals and medical device registrations, contributing to the growth of the pharma industry.
What's more, to accelerate its innovation, it's has strengthened policy incentives – establishing innovation centers and fostering on collaboration between research institutes and enterprises. It has also paved the way for the announcement of sci-tech projects and the recruitment of first-class talent.
Furthermore, the zone has improved its business environment by providing better services to enterprises and enhancing its infrastructure.
It has cultivated and supported small and medium-sized enterprises, upgraded commercial streets and developed industrial clusters.
The efforts are widely said to have resulted in an increase in the zone's revenue and the creation of a favorable environment for business growth.
Overall, the Taizhou Medical High Tech Zone is nowadays widely said to be realizing its potential as a leading biomedical hub – attracting investments, accelerating innovation and providing a conducive business ecosystem for the healthcare industry.